Spero Q3 net loss $3.2M, revenue $25.5M on $30M GSK milestone; FDA SPA for Phase 3 tebipenem HBr

Spero Therapeutics, Inc.

2023-Q3 EPS reported -$0.54 revenue$30,259,000

Net loss $3.2M ($0.06/shr) vs $11.7M loss ($0.33/shr) YoY; revenue $25.5M vs $2.0M YoY driven by $23.2M GSK collaboration revenue.
Cash $93.8M expected to fund operations into H2 2025; received $30M development milestone from GSK under tebipenem HBr license.
FDA granted Special Protocol Assessment for Phase 3 PIVOT-PO trial of oral tebipenem HBr in cUTI/AP; enrollment start expected Q4 2023.
Phase 2a SPR720 trial for NTM-PD ongoing; topline data expected H2 2024. IND for SPR206 planned Q4 2023.
Sath Shukla appointed President and CEO (Aug 1); Esther Rajavelu named CFO and CBO (Nov 1), replacing prior CFO role.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Spero Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-276030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.